目的 探究益心康泰聯(lián)合硝苯地平治療冠心病心絞痛的臨床效果與安全性。方法 選取2014年6月—2016年3月在河南省人民醫(yī)院就診的冠心病心絞痛患者120例，隨機(jī)分為對照組和治療組，每組各60例。對照組口服硝苯地平片，2片/次，3次/d。治療組患者在對照組治療基礎(chǔ)上口服益心康泰膠囊，2粒/次，3次/d。兩組患者均連續(xù)治療2個月。觀察兩組的臨床療效，比較兩組治療前后血清學(xué)指標(biāo)、西雅圖心絞痛量表評分和癥狀積分的變化情況。結(jié)果 治療后，對照組和治療組的總有效率分別為81.67%、95.00%，兩組比較差異具有統(tǒng)計學(xué)意義（P<0.05）。治療后，兩組患者血清脂蛋白a、肌鈣蛋白I和C反應(yīng)蛋白水平均顯著降低，同組治療前后比較差異有統(tǒng)計學(xué)意義（P<0.05）；治療后，治療組血清脂蛋白a、肌鈣蛋白I和C反應(yīng)蛋白水平均顯著低于對照組，兩組比較差異具有統(tǒng)計學(xué)意義（P<0.05）。治療后，兩組西雅圖心絞痛量表評分顯著升高，而癥狀積分顯著降低，同組治療前后比較差異有統(tǒng)計學(xué)意義（P<0.05）；治療后，治療組西雅圖心絞痛量表評分顯著高于對照組，而癥狀積分低于對照組，兩組比較差異具有統(tǒng)計學(xué)意義（P<0.05）。結(jié)論 益心康泰聯(lián)合硝苯地平治療冠心病心絞痛療效顯著，可顯著降低血清生化指標(biāo)和癥狀評分，提高西雅圖心絞痛量表評分，具有一定的臨床推廣應(yīng)用價值。

Objective To investigate the clinical efficacy and safety of Yixin Kangtai Capsules combined with nifedipine in treatment of coronary heart disease angina pectoris. Methods 120 Patients with coronary heart disease angina pectoris in Henan Provincial People's Hospital from June 2014 to March 2016 were randomly divided into control (60 cases) and treatment (60 cases) groups. Patients in the control group were po administered with Nifedipine Tablets, 2 tablets/time, three times daily. Patients in the treatment group were po administered with Yixin Kangtai Capsules on the basis of the control group, 2 grains/time, three times daily. Patients in two groups were treated for 2 months. After treatment, the clinical efficacy was evaluated, and the changes of serological indicators, seattle angina scale score and symptom score in two groups before and after treatment were compared. Results After treatment, the clinical efficacy in the control and treatment group were 81.67% and 95.00%, and there were differences between two groups (P<0.05). After treatment, lipoprotein a, troponin I and CRP in the two groups were significantly decreased, and there were differences in the same group (P<0.05). After treatment, lipoprotein a, troponin I and CRP in the treatment group were lower than those in the control group, and there were differences between two groups (P<0.05). After treatment, seattle angina scale score in the two groups was significantly increased, but symptom score was significantly decreased, and there were differences in the same group (P<0.05). After treatment, seattle angina scale score in the treatment group was higher than that in the control group, but symptom score was significantly lower than that in the control group, and there were differences between two groups (P<0.05).Conclusion Yixin Kangtai Capsules combined with nifedipine has significant effect in treatment of coronary heart disease angina pectoris, and can significantly reduce serum biochemical indicators and symptom score, and also can improve seattle angina pectoris scale score, which has a certain clinical application value.